Cardiac muscle regeneration using mesenchymal stem cells
View Patent ↗Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
1. A method for producing cardiomyocytes in the heart of an individual, comprising:
administering directly to the heart of the individual a cardiomyocyte producing amount of allogeneic mesenchymal stem cells, wherein the mesenchymal stem cells differentiate into cardiomyocytes in the heart of the individual.
2. The method of claim 1 , wherein the mesenchymal stem cells are administered in a suspension containing about 10 to about 40×10 6 of the mesenchymal stem cells/ml.
3. The method of claim 2 , wherein the cell suspension is at least about 500 μl.
4. The method of claim 1 , wherein the mesenchymal stem cells are administered in a pharmaceutically acceptable liquid injectable carrier.
5. The method of claim 1 wherein the mesenchymal stem cells are human.
6. The method of claim 1 , wherein the mesenchymal stem cells are administered by intracardiac injection.
7. The method of claim 1 , wherein the individual has cardiac muscle that has been damaged through disease.
8. The method of claim 1 , wherein the individual has experienced a myocardial infarction.
9. The method of claim 1 , wherein the mesenchymal stem cells are administered directly to at least one damaged portion of heart tissue.
10. The method of claim 1 , wherein the mesenchymal stem cells are administered during an open surgical procedure.
11. A method for producing cardiomyocytes in the heart of an individual, comprising:
administering directly to the heart of the individual a cardiomyocyte producing amount of autologous mesenchymal stem cells, wherein the mesenchymal stem cells differentiate into cardiomyocytes in the heart of the individual.
12. The method of claim 11 , wherein the mesenchymal stem cells are administered as a suspension containing about 10 to about 40×10 6 of the mesenchymal stem cells/ml.
13. The method of claim 12 , wherein the cell suspension is at least about 500 μl.
14. The method of claim 11 , wherein the mesenchymal stem cells are administered in a pharmaceutically acceptable liquid injectable carrier.
15. The method of claim 11 wherein the mesenchymal stem cells are human.
16. The method of claim 11 , wherein the mesenchymal stem cells are administered by intracardiac injection.
17. The method of claim 11 , wherein the individual has cardiac muscle that has been damaged through disease.
18. The method of claim 11 , wherein the individual has experienced a myocardial infarction.
19. The method of claim 11 , wherein the mesenchymal stem cells are administered directly to at least one damaged portion of heart tissue.
20. The method of claim 11 , wherein the mesenchymal stem cells are administered during an open surgical procedure.